Cipla in no hurry to launch semaglutide as Yurpeak gains traction

Cipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its launch. The company may not launch generic semaglutide if Yurpeak demand continues. Cipla will re-evaluate semaglutide opportunities in international markets later. Yurpeak's doctor acceptance and distribution give Cipla a competitive edge.